Urine DNA Methylation Panel for Prostate Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting prostate cancer, particularly aggressive forms, are plagued by low tumor specificity, high false-positive rates, and the need for invasive biopsies, leading to overtreatment and unnecessary healthcare burdens.
Innovation Solution
The development of an epigenetic Cancer of the Prostate test in urine (epiCaPture), which uses a panel of at least 6 genes and an internal control gene to detect methylated regulatory DNA sequences in urine samples, providing a non-invasive means to identify high-risk, potentially lethal prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PSA testing is used for early detection of prostate cancer, then screening coverage is improved, but tumor specificity deteriorates leading to high false-positive rates
Solution Approach 1:
The invention segments the detection process by using a multi-gene methylation panel (GSTP1, SFRP2, IGFBP3, IGFBP7, APC, PTGS2) instead of a single PSA marker. Each gene targets specific molecular pathways dysregulated in prostate cancer, collectively improving tumor specificity while maintaining screening coverage through urine-based detection.
Solution Approach 2:
The invention changes the detection parameter from PSA protein levels to DNA methylation status of multiple genes. Methylation is an epigenetic modification that occurs early in carcinogenesis and is highly specific to cancer cells, thereby improving tumor specificity while allowing non-invasive urine-based detection.
2Measurement precision
If PSA testing with high sensitivity cutoff is used, then detection sensitivity is improved, but false-positive rate increases leading to unnecessary biopsies
Solution Approach 1:
The invention divides the detection into multiple independent gene markers, each contributing to the overall diagnostic accuracy. The multi-gene panel approach allows for better discrimination between cancer and benign conditions, reducing false-positives while maintaining high sensitivity for detecting aggressive prostate cancer.
Solution Approach 2:
The invention replaces the mechanical/invasive biopsy system with a molecular detection system based on DNA methylation analysis. By detecting epigenetic changes in urine DNA, the test identifies cancer with high sensitivity without requiring tissue sampling, thereby eliminating the harmful effects of unnecessary biopsies.
3Measurement precision
If invasive TRUS-biopsy is performed to confirm diagnosis, then diagnostic accuracy is improved, but patient burden and healthcare cost increase
Solution Approach 1:
The invention introduces urine-based methylation detection as an intermediary test between PSA screening and invasive biopsy. This intermediate molecular test provides sufficient diagnostic accuracy to confirm or rule out cancer without requiring biopsy, thereby reducing patient burden while maintaining diagnostic precision.
Solution Approach 2:
The invention substitutes the mechanical biopsy procedure with a molecular analysis of urine DNA. By detecting methylation patterns in shed urinary cells, the test achieves diagnostic accuracy comparable to or exceeding biopsy while being non-invasive, thereby eliminating patient burden associated with needle biopsies.
4Measurement precision
If multi-gene methylation panel is used, then tumor specificity is improved, but test complexity increases
Solution Approach 1:
The invention uses a universal urine sample that can be collected non-invasively from any patient. This single sample type serves multiple functions: it contains DNA from shed prostate cells, allows detection of methylation patterns across multiple genes, and eliminates the need for different sample collection methods, thereby managing complexity while improving specificity.
Solution Approach 2:
The invention changes the detection parameter to DNA methylation status, which can be analyzed using standardized molecular biology techniques. By targeting specific CpG islands in promoter regions of multiple genes, the test achieves high tumor specificity through epigenetic modifications that are consistent and detectable using established methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The epiCaPture test offers improved tumor specificity compared to PSA testing, selectively identifies high-risk prostate cancer, and reduces the need for unnecessary biopsies, thereby alleviating overtreatment and associated healthcare burdens.
Implementation Method 1
a DNA-methylation test for prostate cancer... the detection of a plurality of biomarkers in a biological sample to distinguish the presence of aggressive prostate cancer from non-aggressive prostate cancer or no cancer
Data Source
Figure 1
Figure 1
Figure 2
AI summary
A method of determining the risk of metastatic prostate cancer in an individual diagnosed with prostate cancer, the method comprising a step of assaying a biological sample obtained from the individual for the presence of at last one methylated regulatory DNA sequence selected from group comprising: SEQUENCE ID No's 1 to 16, or variants thereof, and correlating the presence or absence of the methylated regulatory DNA sequence with aggressive (metastatic) prostate cancer.